Meeting
2024 ASCO Genitourinary Cancers Symposium
Datopotamab deruxtecan in locally advanced/metastatic urothelial cancer: Preliminary results from the phase 1 TROPION‑PanTumor01 study.
Authors
Aaron Lisberg
Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA
Aaron Lisberg , Alexandra Drakaki , Funda Meric-Bernstam , Omar Alhalabi , Takahiro Kojima , Manabu Kato , Alexander I. Spira , Mohamad Adham Salkeni , Rebecca Heist , Xin Gao , Manali A. Bhave , Gunnar Klauss , Hayato Sakaki , Yasuyuki Kakurai , TAKAHIRO KOGAWA
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03401385
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 603)
DOI
10.1200/JCO.2024.42.4_suppl.603
Abstract #
603
Poster Bd #
G9
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors.
First Author: Fei Ma
Poster
2023 ASCO Annual Meeting
HH2853, an EZH1/2 inhibitor, in patients with epithelioid sarcoma: Preliminary results from the phase 1 part of a first-in-human phase I/II study.
First Author: Zhengfu Fan
Poster
2022 ASCO Gastrointestinal Cancers Symposium
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.
First Author: Tanios S. Bekaii-Saab
Poster
2021 ASCO Annual Meeting
BEGONIA: Phase 1b/2, open-label, platform study of the safety and efficacy of durvalumab (D) ± paclitaxel (P) with novel oncology therapies for first‑line metastatic triple-negative breast cancer (mTNBC): Addition of arm 7, D + datopotamab deruxtecan (Dato-DXd; DS-1062).
First Author: Peter Schmid